Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen(Institute of Oncology Research), Neal D. Shore(Carolina Urologic Research Center), Karim Fizazi(Université de Lille), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Charles J. Ryan(University of Minnesota), Michael J. Morris(Dana-Farber Cancer Institute), Byung Ha Chung, Felix Y. Feng(University of Michigan), Robert G. Bristow(Princess Margaret Cancer Centre), Daniel Castellano(Universidad Complutense de Madrid), Charles G. Drake(Columbia University Irving Medical Center), Mark A. Rubin(University of Bern), Raja B. Khauli(American University of Beirut Medical Center), Brett S. Carver(Memorial Sloan Kettering Cancer Center), Anwar R. Padhani(Mount Vernon Cancer Centre), Himisha Beltran(Dana-Farber Cancer Institute), Axel Heidenreich(Centrum für Integrierte Onkologie), Gedske Daugaard(Copenhagen University Hospital), Tomasz M. Beer(Exact Sciences (United States)), Vedang Murthy(Homi Bhabha National Institute), Susan Halabi(Duke Medical Center), Fred Saad(Centre Hospitalier de l’Université de Montréal), Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne), Philip W. Kantoff(Convergent Science (United States)), Stefano Fanti(Azienda USL di Bologna), Martin Gleave(University of British Columbia), Colin C. Pritchard(Animal and Plant Health Agency), Ian D. Davis(Austin Health), Noel W. Clarke(The Christie NHS Foundation Trust), Mark Frydenberg(Monash University), Avishay Sella(Institute of Cancer Research), Alicia K. Morgans(Dana-Farber Cancer Institute), Gero Kramer(Memorial Sloan Kettering Cancer Center), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Oliver Sartor(Mayo Clinic), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Piet Ost(Ghent University Hospital), Rodolfo Borges dos Reis(Universidade de São Paulo), Christopher P. Evans(University of Nevada, Reno), Mack Roach(University of California, San Francisco), Chris Parker(Royal Marsden NHS Foundation Trust), Alberto Bossi(Institut Gustave Roussy), Pirkko‐Liisa Kellokumpu‐Lehtinen, Fernando Cotait Maluf(Hospital Israelita Albert Einstein), Gerhardt Attard(London Cancer), Chris Logothetis(The University of Texas MD Anderson Cancer Center), Celestia S. Higano(University of British Columbia)
Cited by 644
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k